Halozyme Therapeutics Expects Proposed Rule to Have Little Impact on Royalties
MT Newswires Live
Jun 15
Halozyme Therapeutics (HALO) expects zero to minimal royalty revenue impact from a proposed rule issued Friday by the US Centers for Medicare & Medicaid Services for the Medicare Drug Price Negotiation Program, the company said Monday.
The company said the projection, based on its analysis of the proposed rule and the statutory framework established under the One Big Beautiful Bill Act, reflects an expected zero to minimal impact on royalty revenue through at least 2035.
The projection is backed by statements within the proposed rule affirming that orphan drug protections remain applicable, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.